Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis

被引：14
作者：
Udayakumar, Suji [1 ]
Parmar, Ambica [2 ,3 ]
Leighl, Natasha B. [4 ]
Everest, Louis [1 ]
Arciero, Vanessa S. [1 ]
Delos Santos, Seanthel [1 ]
Rahmadian, Amanda [1 ]
Doherty, Mark K. [1 ,3 ,7 ]
Chan, Kelvin K. W. [1 ,3 ,5 ,6 ]
机构：
[1] Sunnybrook Res Inst, Toronto, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Toronto, ON, Canada
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Canadian Ctr Appl Res Canc Control, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, 2075 Bayview Ave T2-058, Toronto, ON M4N 3M5, Canada
[7] St Vincents Univ Hosp, Elm Pk, Dublin, Ireland
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 173卷
关键词：
Pembrolizumab; Chemotherapy; Non-small-cell lung cancer; Systematic review; Network meta-analysis; Survival; IMMUNE CHECKPOINT INHIBITORS; MEAN SURVIVAL-TIME; HAZARD RATIO; 1ST-LINE NIVOLUMAB; PD-L1; EXPRESSION; STAGE IV; THERAPY; TRIALS; INTERVENTIONS; COMBINATION;
D O I：
10.1016/j.critrevonc.2022.103660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pembrolizumab monotherapy has replaced chemotherapy as first-line treatment for patients with metastatic non small-cell lung cancer with tumor programmed death-ligand 1 expression > 50%. The benefit of chemotherapy combined with pembrolizumab, as compared to pembrolizumab monotherapy, remains uncertain. This systematic review and network meta-analysis aimed to compare these therapies through a network of randomized controlled trials. Endpoints evaluated were progression-free survival (PFS) and overall survival (OS) expressed as hazard ratio (HR) and restricted mean survival time (RMST) through reconstruction of individual patient data from Kaplan-Meier curves, and objective response rate and adverse events. Four trials were included. Through HR and RMST, combination therapy demonstrated longer PFS and similar OS as compared to pembrolizumab monotherapy. Combination therapy was associated with an increase in response rate and adverse events. Thus, combination therapy can be considered when rapid response or prevention of rapid progression is needed. Further evidence to directly compare these therapies is required.
引用
收藏
页数：8
相关论文
共 50 条
[1]   A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis [J].
Abrahao, Ana B. K. ;
Ko, Yoo-Joung ;
Berry, Scott ;
Chan, Kelvin K. W. .
CLINICAL COLORECTAL CANCER, 2018, 17 (02) :113-120
[2]   Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].
Aguilar, E. J. ;
Ricciuti, B. ;
Gainor, J. F. ;
Kehl, K. L. ;
Kravets, S. ;
Dahlberg, S. ;
Nishino, M. ;
Sholl, L. M. ;
Adeni, A. ;
Subegdjo, S. ;
Khosrowjerdi, S. ;
Peterson, R. M. ;
Digumarthy, S. ;
Liu, C. ;
Sauter, J. ;
Rizvi, H. ;
Arbour, K. C. ;
Carter, B. W. ;
Heymach, J. V. ;
Altan, M. ;
Hellmann, M. D. ;
Awad, M. M. .
ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659
[3]  
[Anonymous], COCHRANE HDB SYSTEMA
[4]   Objective response rate assessment in oncology: Current situation and future expectations [J].
Aykan, Nuri Faruk ;
Ozatli, Tahsin .
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2020, 11 (02) :53-73
[5]   Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) [J].
Brueckl, Wolfgang M. ;
Ficker, Joachim H. ;
Zeitler, Gloria .
BMC CANCER, 2020, 20 (01)
[6]   First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].
Carbone, D. P. ;
Reck, M. ;
Paz-Ares, L. ;
Creelan, B. ;
Horn, L. ;
Steins, M. ;
Felip, E. ;
van den Heuvel, M. M. ;
Ciuleanu, T. -E. ;
Badin, F. ;
Ready, N. ;
Hiltermann, T. J. N. ;
Nair, S. ;
Juergens, R. ;
Peters, S. ;
Minenza, E. ;
Wrangle, J. M. ;
Rodriguez-Abreu, D. ;
Borghaei, H. ;
Blumenschein, G. R. ;
Villaruz, L. C. ;
Havel, L. ;
Krejci, J. ;
Corral Jaime, J. ;
Chang, H. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Chen, A. C. ;
Socinski, M. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426
[7]   A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer [J].
Chan, Kelvin ;
Shah, Keya ;
Lien, Kelly ;
Coyle, Doug ;
Lam, Henry ;
Ko, Yoo-Joung .
PLOS ONE, 2014, 9 (10)
[8]  
Clinical Practice Living Guidelines, CLIN PRACT LIV GUID
[9]   Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis [J].
Dafni, Urania ;
Tsourti, Zoi ;
Vervita, Katerina ;
Peters, Solange .
LUNG CANCER, 2019, 134 :127-140
[10]   A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma [J].
Delos Santos, S. ;
Udayakumar, S. ;
Nguyen, A. ;
Ko, Y. J. ;
Berry, S. ;
Doherty, M. ;
Chan, K. K. W. .
CURRENT ONCOLOGY, 2020, 27 (06) :300-306
12345